Kuhnil Pharm acquires approval of Omega-3/rosuvastatin combination drug for first time in the world
Kuhnil Pharm(CEO Young-Joong Kim) announced approval of Rosumega SC(generic name: omega-3-acids ethyl esters 90 + rosuvastatin) from the Ministry of Food and Drug Safety on the 31st of July.
Rosumega SC will be used to treat combined dyslipidemia, which a level of LDL cholesterol is properly con...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
